Next-generation sequencing (NGS) identified KRAS G12V and PTCH1 E340V mutations, and immunohistochemical (IHC) staining indicated negative PD-L1 expression (tumor proportion score, TPS < 1%). Here, KRAS is linked to neoplasm.